MLYS Bathi saben saham sajrone rolas wulan pungkasan Mineralys

Logo perusahaan publik Mineralys Therapeutics (MLYS)

The prospects for Mineralys Therapeutics (MLYS) are driven by the development of a drug for severe hypertension and the potential for an acquisition by a Big Pharma behemoth. The TTM earnings per share trend confirms the financial status, where -4.32 is the current level of the metric. The team consists of top cardiologists motivated by stock options. However, betting on a single asset creates binary risks that entirely determine the startup's fate.

MLYS (Mineralys Therapeutics) riwayat Bathi resik saben saham (EPS TTM) saka 28.04.2023 nganti 17.11.2026

Rincian analitis lan laporan data perusahaan Mineralys Corp (MLYS)

- rega saham lan target rega konsensus:
Analisis fundamental perusahaan:Mineralys Therapeutics, Inc. - MLYS
Barang unggulan Mineralys Therapeutics Inc

The dynamics of this multiple allow for an assessment of the real efficiency of profit generation per share of capital, excluding the impact of the total emission volume. By analyzing the net income per share over the last 12 months, an investor can see the financial stability of Mineralys Therapeutics (MLYS), whose capitalization is supported by the development of breakthrough drugs for the treatment of severe hypertension in cardiology.